PT - JOURNAL ARTICLE AU - Graves, John AU - Garbett, Shawn AU - Zhou, Zilu AU - Schildcrout, Jonathan S. AU - Peterson, Josh TI - Comparison of Decision Modeling Approaches for Health Technology and Policy Evaluation AID - 10.1101/2020.05.26.20113845 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.26.20113845 4099 - http://medrxiv.org/content/early/2020/05/28/2020.05.26.20113845.short 4100 - http://medrxiv.org/content/early/2020/05/28/2020.05.26.20113845.full AB - We discuss tradeoffs and errors associated with approaches to modeling health economic decisions. Through an application in pharmacogenomic (PGx) testing to guide drug selection for individuals with a genetic variant, we assessed model accuracy, optimal decisions and computation time for an identical decision scenario modeled four ways: using (1) coupled-time differential equations [DEQ]; (2) a cohort-based discrete-time state transition model [MARKOV]; (3) an individual discrete-time state transition microsimulation model [MICROSIM]; and (4) discrete event simulation [DES]. Relative to DEQ, the Net Monetary Benefit for PGx testing (vs. a reference strategy of no testing) based on MARKOV with rate-to-probability conversions using commonly used formulas resulted in different optimal decisions. MARKOV was nearly identical to DEQ when transition probabilities were embedded using a transition intensity matrix. Among stochastic models, DES model outputs converged to DEQ with substantially fewer simulated patients (1 million) vs. MICROSIM (1 billion). Overall, properly embedded Markov models provided the most favorable mix of accuracy and run-time, but introduced additional complexity for calculating cost and quality-adjusted life year outcomes due to the inclusion of “jumpover” states after proper embedding of transition probabilities. Among stochastic models, DES offered the most favorable mix of accuracy, reliability, and speed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFinancial support for this study was provided by the NIH Common Fund (U01HL122904) and the National Human Genome Research Institute (1R01HG009694-01). The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work does not draw on human subjects data, though the parent grant (1R01HG009694-01) was reviewed and approved by the Institutional Review Board at Vanderbilt University Medical Center.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll replication code and data for this manuscript is available as part of the supplementary material. Please contact the lead author (Graves) for access.